Bridging Science to Life
JN Biosciences LLC
320 Logue Avenue
Mountain View, CA 94043
September 17, 2018
The therapeutic activity of HuABC2 in kidney transplantation was reported in a paper entitled "CD122 signaling in CD8+ memory T cells drivescostimulation-independent rejection" by Mathews et al. (J. Clin. Invest. online published on Sept. 17, 2018). HuABC2 with belatacept (CTLA4-Ig, Nulojix®) prolonged monkey survival much better than belatacept alone in a life-sustaining fully-MHC-mismatched renal allograft study. While HuABC2 together with belatacept effectively suppressed immune reactions against renal allografts, suppression of Treg cells was not observed. This study was conducted as a collaboration between JN Biosciences and Dr. Andrew Adams' lab at Emory University.
September 12, 2018
A phase 1 clinical study sponsored by Gilead Sciences to evaluate the safety, tolerability, PK, PD, and clinical activity of a humanized anti-TIGIT IgG1 monoclonal antibody (AB154, domvanalimab) was initiated for treatment of non-small cell lung cancer (NCT03628677). The title of the study is "A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies."
August 21, 2018
A new U.S. patent (10053517) was issued for JN Biosciences' MultYmab™ antibody engineering platform, which strengthens the company's IP position for application of this technology to generate potent agonist antibodies against a wide range of membrane-bound proteins, including immune costimulatory molecules such as OX40, 4-1BB and ICOS, that trigger signal transduction upon multivalent cross-linking.
July 18, 2018
The potent therapeutic activity of an anti-CD122 antibody for treatment of vitiligo in a mouse disease model was published in a paper entitled "Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo" (Richmond et al., Science Translational Medicine 2018 10:eaam7710). Short-term administration of anti-CD122 either systemically or locally in the skin provided durable repigmentation in mice with established vitiligo. This study was conducted as a collaboration between JN Biosciences and Dr. John Harris' lab at University of Massachusetts.
January 25, 2018
The positive therapeutic effect of an anti-CD122 antibody on type I diabetes in a NOD mouse model, which was carried out as a collaboration between JN Biosciences and Dr. Wenxian Fu's lab at University of California at San Diego, was published in a paper entitled "CD122 blockade restores immunological tolerance in autoimmune type 1 diabetes via multiple mechanisms" (Yuan et al. JCI insight 2018 3(2):e96600). Anti-CD122 (ChMBC7) treatment selectively ablated NK and CD8+ T cells, but not Treg cells, from pancreatic islets in NOD mice, and restored immune tolerance in type 1 diabetes.
Copyright 2022 JN Biosciences. All rights reserved.
JN Biosciences LLC
320 Logue Avenue
Mountain View, CA 94043